EXC vs SPRY · P/E 17, rev $24.26B vs rev $56.3M
Exelon Corporation (EXC) versus ARS Pharmaceuticals, Inc (SPRY) — a side-by-side from cached financials, not a winner call.
Exelon Corporation (EXC) is a utilities - regulated electric company listed on NASDAQ.
ARS Pharmaceuticals, Inc (SPRY) is a biotechnology company listed on NASDAQ.
Latest reported EXC revenue for 2025-12-31 was $24.26B. Net income was $2.77B. Revenue was up 5.3% from 2024-12-31 to 2025-12-31. EXC currently screens at market cap $47.33B and trailing P/E 16.8.
Latest reported SPRY revenue for 2026-06-30 was $56.3M. Net income was -$123.0M. SPRY currently screens at market cap $983.1M.
EXC currently screens at market cap $47.33B and trailing P/E 16.8. SPRY currently screens at market cap $983.1M.
Not investment advice. Open the EXC and SPRY stock pages for the full models.
Not investment advice.